The results of the “frontMIND” phase III trial that compares an intensified treatment (i.e., the anti-CD19 tafasitamab monoclonal antibody plus lenalidomide plus R-CHOP vs. R-CHOP) in newly diagnosed high-intermediate and high-risk DLBCL patients, will only be available in the next years [27]. This evidence concerns the gene DDIT3 and diffuse large B-cell lymphoma.